Core Viewpoint - A class action lawsuit has been initiated against Novo Nordisk A/S, alleging that the company made false or misleading statements regarding its CagriSema obesity study, leading to significant investor losses during the specified class period from November 2, 2022, to December 19, 2024 [1][3]. Group 1: Class Action Details - The class action represents investors who purchased securities during the class period and have until March 25, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that Novo Nordisk failed to disclose critical information about the reliability of its projected success for the Phase 3 CagriSema obesity study, "REDEFINE-1" [5]. Group 2: Study Results and Impact - On December 20, 2024, Novo Nordisk reported results from the REDEFINE-1 trial, indicating that only 57.3% of CagriSema patients remained on the highest dose after 68 weeks, compared to 82.5% for cagrilintide 2.4 mg and 70.2% for semaglutide 2.4 mg [3]. - Following the release of these results, Novo Nordisk's stock price experienced a nearly 18% drop [3]. Group 3: Allegations of Misrepresentation - The lawsuit alleges that the company's claims regarding CagriSema achieving at least 25% weight loss in the REDEFINE-1 study were unrealistic [5]. - It is suggested that the study's "flexible protocol" limited its ability to provide meaningful weight loss data, indicating potential tolerability issues or a rushed patient selection process [5].

Core Viewpoint - Roche's collaboration deal with Zealand Pharma for the obesity drug petrelintide increases competition in the obesity treatment market, negatively impacting Novo Nordisk's stock performance [1][5]. Company Summary - Roche has entered a licensing agreement to co-develop petrelintide, a long-acting amylin analog, which is currently in phase IIb studies targeting individuals who are obese or overweight without type II diabetes [2][4]. - The deal includes an upfront payment of $1.65 billion, with total deal value reaching approximately $5.3 billion, including milestone payments [4]. - Novo Nordisk's stock has seen a significant decline of 14.2% this week and 44.4% over the past year, attributed to increased competition and disappointing data from its own obesity candidate, CagriSema [6][7]. Industry Summary - The obesity treatment market is becoming increasingly competitive, with Roche's entry posing a threat to the dominance of Novo Nordisk and Eli Lilly, who currently lead with their GLP-1 drugs [3][5]. - Other companies, such as Amgen and Viking Therapeutics, are also advancing in the development of GLP-1-based candidates, indicating a broader competitive landscape [8]. - The recent licensing of GUB014295 by AbbVie for obesity treatment further intensifies competition in the next-generation amylin class [9].

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submiss ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form/?id=135472&from=4 CLASS PERIOD: November 2, 2022 to ...

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S due to alleged securities fraud affecting investors between November 2, 2022, and December 19, 2024 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors impacted by the company's underperformance in the "REDEFINE 1" trial, which reported a weight loss of 22.7% after 68 weeks, falling short of the expected 25% [2] - Following the announcement of the trial results, Novo's stock price dropped by $18.44, closing at $85.00 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Novo Nordisk (NVO) has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema, in patients with obesity and type 2 diabetes (T2D) and a mean baseline body weight of 102 kg. The results showed that treatment with the candidate led to a statistically significant and superior weight loss at week 68 compared with placebo.NVO’s CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. T ...

Core Insights - Novo Nordisk A/S announced results from the REDEFINE 2 phase 3 trial, which investigated the efficacy and safety of CagriSema, a combination of cagrilintide and semaglutide, in patients with obesity or overweight and type 2 diabetes [1][6] Trial Overview - The REDEFINE 2 trial lasted 68 weeks and included 1,206 randomized participants with a mean baseline body weight of 102 kg [1] - The trial allowed for flexible dosing modifications by patients throughout the study [2] Efficacy Results - After 68 weeks, patients treated with CagriSema achieved a weight loss of 15.7%, compared to 3.1% with placebo [3] - A co-primary endpoint of weight loss of 5% or more was achieved by 89.7% of patients on CagriSema, versus 30.3% for placebo [4] - When applying the treatment policy estimand, CagriSema resulted in a weight loss of 13.7% compared to 3.4% with placebo [4] Safety Profile - CagriSema demonstrated a safe and well-tolerated profile, with the most common adverse events being mild to moderate gastrointestinal issues that diminished over time [5] Future Outlook - Novo Nordisk plans to file for the first regulatory approval of CagriSema in Q1 2026, with detailed results from both REDEFINE 1 and REDEFINE 2 expected to be presented at a scientific conference in 2025 [6] Market Reaction - Following the announcement, NVO stock increased by 0.49% to $79.35 during the premarket session [7]

Core Viewpoint - Shares of Novo Nordisk A/S (NVO) have declined following disappointing phase 3 results for CagriSema, which was unexpected given the anticipated consensus shift in treatment approaches [2] Group 1: Company Performance - Novo Nordisk A/S reported underwhelming phase 3 results for its drug CagriSema, leading to a drop in its stock price [2] Group 2: Market Reaction - The market's reaction to the phase 3 results was surprising, indicating a potential disconnect between investor expectations and the actual outcomes [2]

Core Insights - Novo Nordisk's stock experienced a significant decline of 8.9% amid broader market losses, with the S&P 500 down 1.7% and the Nasdaq Composite down 2.8% [1] Group 1: Trial Results - The trial results for Novo Nordisk's next-generation weight-loss drug CagriSema showed a weight loss of 15.7% in obese or overweight adult patients with type 2 diabetes, falling short of the expected 25% [2] - The disappointing results for CagriSema come at a critical time, as the company had positioned it as a successor to its successful weight-loss drugs Wegovy and Ozempic, which have been significant revenue generators [3] Group 2: Market Position - Despite the setback with CagriSema, Novo Nordisk is expanding its market presence by launching an online pharmacy, NovoCare, allowing consumers to purchase Wegovy at a discounted price of $499 per month [4] - CagriSema, while not meeting high expectations, still demonstrated solid weight loss compared to placebo and is considered to have a safe and well-tolerated profile, suggesting that Novo Nordisk remains well-positioned in the lucrative weight-loss drug market [5]

Core Insights - Novo Nordisk's shares declined over 9% following the announcement of the Redefine 2 trial results for its weight-loss drug CagriSema, which showed a 15.7% weight loss in patients on the highest dose compared to 3.1% in the placebo group [1][2]. Group 1: Trial Results - The Redefine 2 trial involved 1,206 participants with obesity or overweight and type 2 diabetes, with a mean baseline body weight of approximately 224 pounds [1]. - In the trial, 61.9% of patients received the highest dose of CagriSema, which combines GLP-1 agonist semaglutide and cagrilintide, a synthetic version of the hormone amylin [4]. - The results confirmed the superior efficacy of CagriSema in the target population, according to Martin Holst Lange, executive vice president for development at Novo Nordisk [6]. Group 2: Market Context - The market reacted negatively to the trial results, with shares of Novo Nordisk falling significantly, reflecting Wall Street's expectations regarding the drug's performance compared to existing products like Ozempic and Wegovy [2]. - Novo Nordisk's revenue exceeded Wall Street expectations in its latest fiscal quarter, but the company anticipates slower sales growth in 2025 due to increasing competition [7]. - In response to competitive pressures, Novo recently halved the cost of its weight-loss drug Wegovy for U.S. patients paying cash through its direct-to-patient online pharmacy [8]. Group 3: Future Plans - Novo Nordisk plans to present detailed results from both the Redefine 1 and Redefine 2 trials at a scientific conference in 2025 and aims to file for regulatory approval of CagriSema in the first quarter of fiscal year 2026 [5].